inclusion criteria: * signed informed consent. * requiring admission to hospital for acute medical care (not for purely public health or quarantine purposes). * current respiratory failure (i.e. receipt of high-flow nasal cannula, non-invasive ventilation, invasive mechanical ventilation, or ecmo (extracorporeal membrane oxygenation) used to treat acute hypoxemic respiratory failure). * sars-cov-2 (covid-19) infection, documented by a nucleic acid test (nat) or equivalent testing with most recent rest within 14 days prior to randomization. * respiratory failure is believed to be due to sars-cov-2 pneumonia.

inclusion criteria: * signed informed consent. * requiring admission to hospital for acute medical care (not for purely public health or quarantine purposes). * current respiratory failure (i.e. receipt of high-flow nasal cannula, non-invasive ventilation, invasive mechanical ventilation, or ecmo (extracorporeal membrane oxygenation) used to treat acute hypoxemic respiratory failure). * sars-cov-2 (covid-19) infection, documented by a nucleic acid test (nat) or equivalent testing with most recent rest within 14 days prior to randomization. * respiratory failure is believed to be due to sars-cov-2 pneumonia.

inclusion criteria: - signed informed consent. - requiring admission to hospital for acute medical care (not for purely public health or quarantine purposes). - current respiratory failure (i.e. receipt of high-flow nasal cannula, non-invasive ventilation, invasive mechanical ventilation, or ecmo (extracorporeal membrane oxygenation) used to treat acute hypoxemic respiratory failure). - sars-cov-2 (covid-19) infection, documented by a nucleic acid test (nat) or equivalent testing with most recent rest within 14 days prior to randomization. - respiratory failure is believed to be due to sars-cov-2 pneumonia.

inclusion criteria: - signed informed consent. - requiring admission to hospital for acute medical care (not for purely public health or quarantine purposes). - current respiratory failure (i.e. receipt of high-flow nasal cannula, non-invasive ventilation, invasive mechanical ventilation, or ecmo (extracorporeal membrane oxygenation) used to treat acute hypoxemic respiratory failure). - sars-cov-2 (covid-19) infection, documented by a nucleic acid test (nat) or equivalent testing with most recent rest within 14 days prior to randomization. - respiratory failure is believed to be due to sars-cov-2 pneumonia.